Scienture Shares Skyrocket 350% on FDA-Approved Drug Launch – What’s Next?
Scienture’s unprecedented Oct. 23 rally was driven by the commercial rollout of Arbli, its first revenue-generating product. The company’s press release on Oct. 23 confirmed that it began sales and shipped first customer orders for Arbli (losartan suspension), immediately triggering the Nasdaq surge finviz.com. CEO/co-CEO Narasimhan Mani said the event “represents a major achievement for Scienture” in moving from development to execution finviz.com. Investors piled in on the news: as Benzinga reported, SCNX shares leapt over 140% on Thursday following word of the launch benzinga.com benzinga.com. The price pop was staggering for a penny stock. Finviz confirmed the stock hit
